Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.1%

9 terminated/withdrawn out of 147 trials

Success Rate

89.8%

+3.3% vs industry average

Late-Stage Pipeline

7 trials in Phase 3/4

Results Transparency

25%

20 of 79 completed trials have results

Key Signals

14 recruiting20 with results6 terminated

Enrollment Performance

Analytics

N/A

35(51.5%)

Phase 2

18(26.5%)

Phase 1

7(10.3%)

Phase 4

6(8.8%)

Early Phase 1

1(1.5%)

Phase 3

1(1.5%)

68Total

N/A(35)

Phase 2(18)

Phase 1(7)

Phase 4(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (147)

Showing 20 of 147 trials

NCT03295279Enrolling By Invitation

WTC Chest CT Imaging Archive

Role: collaborator

NCT02968212Phase 2Active Not Recruiting

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

Role: collaborator

NCT02918409Phase 4Completed

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

Role: lead

NCT05313087Completed

COVID-19 Vaccine Response in Chronic Respiratory Conditions

Role: lead

NCT03994380Phase 1Completed

Use of DNAse in Neutrophilic Asthma

Role: lead

NCT02323100Phase 1Terminated

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

Role: lead

NCT03035097Recruiting

Deployment-Related Lung Disease Research Database and Biorepository

Role: lead

NCT03241420Active Not Recruiting

Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease

Role: lead

NCT05182372Not ApplicableRecruiting

Enhancing Digital CBT-I to Improve Adherence and Reduce Disparities

Role: collaborator

NCT04353752Completed

Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs

Role: lead

NCT04354038Completed

Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations

Role: lead

NCT04341532Completed

Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations

Role: lead

NCT04844359Active Not Recruiting

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Role: lead

NCT05730283Phase 2Recruiting

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Role: collaborator

NCT07420530Early Phase 1Recruiting

Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion

Role: collaborator

NCT03742414Phase 2Active Not Recruiting

Seal, Stopping Eczema and Allergy Study

Role: collaborator

NCT07071324Not ApplicableRecruiting

CF Wellness Program

Role: collaborator

NCT03672630Phase 2Completed

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Role: collaborator

NCT06435520Phase 4Recruiting

Enhancing Hypnotic Medication Discontinuation in Primary Care

Role: lead

NCT01969344Active Not Recruiting

Study of COPD Subgroups and Biomarkers

Role: collaborator